Exchange: NASDAQ·Updated 04:04 PM EST
NVCT logo

NVCT Nuvectis Pharma Inc

$20.29
$1.09
(5.68%)
Today
Closed $20.29
$0.00
(0.00%)
After Hours
Reported EarningsNov 4
Mkt Cap$660.27M
Vol186,306.00

About NVCT

Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. Its product pipeline includes NXP800 and NXP900. The company was founded by Ronald E. Bentsur, Enrique Poradosu, and Shay Shemesh on July 27, 2020 and is headquartered in Fort Lee, NJ.
43

Bearish Sentiment

How do you feel about NVCT?

UNLV
$NVCT Once promised 2026 data readouts for NXP900 1b mono and resistance combo therapies now 1H 2027. Insiders not selling and my PT. Deprioritizing assets understandable for asset rich small biotech. NXP100 will be muti billion blockbuster by itself for this 600M market cap. GLSI another small biotech stock I'm very deep
3
Goodstockday
$NVCT Anyone have a theory about this stock price fall? I find the results very encouraging - great depth of response including some complete responses.
1
Rambonius
$NVCT Key Highlights Strong efficacy: A 40% response rate in high-grade glioma (HGG), including three complete responses among 20 patients. Exceptional response depth: 87.5% of HGG responders achieved greater than 80% tumor reduction. Activity after prior BRAF treatment: Two of three previously treated patients achieved deep partial responses exceeding 80% tumor reduction, remaining on therapy beyond 14 and 17 months. Encouraging survival: Median overall survival of 17.2 months and a 94.4% one-year survival rate in HGG. Favorable safety: Only 14.3% experienced grade ≥3 treatment-related adverse events, with no treatment discontinuations due to adverse events. Broader potential: An improved salt formulation has shown promising activity in non-CNS tumors, with larger clinical studies underway. Valuation Upside: Largely treated as a free call option, NXP200’s emerging clinical evidence should support a meaningful recognition of its value,.
1
Rambonius
$NVCT Truffle pigs post today: Key Highlights Strong efficacy: A 40% response rate in high-grade glioma (HGG), including three complete responses among 20 patients. Exceptional response depth: 87.5% of HGG responders achieved greater than 80% tumor reduction. Activity after prior BRAF treatment: Two of three previously treated patients achieved deep partial responses exceeding 80% tumor reduction, remaining on therapy beyond 14 and 17 months. Encouraging survival: Median overall survival of 17.2 months and a 94.4% one-year survival rate in HGG. Favorable safety: Only 14.3% experienced grade ≥3 treatment-related adverse events, with no treatment discontinuations due to adverse events. Broader potential: An improved salt formulation has shown promising activity in non-CNS tumors, with larger clinical studies underway. Valuation Upside: Largely treated as a free call option, NXP200’s emerging clinical evidence should support a meaningful recognition of its value, beyond the NXP100
1
shoc24
$NVCT reported earnings before the open today. GAAP EPS missed estimates: -$1.02 vs. -$0.24 expected, according to Stock Meadow.
StocktwitsEarnings
$NVCT Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.20 up 54.55% YoY • Nuvectis Pharma expects research and development expenses to increase substantially in the near term and beyond, and general and administrative expenses to increase in the future as headcount expands to support development and corporate activities.

Advertisement|Remove ads.